MaaT Pharma (EURONEXT: MAAT – the “Company”), a late-stage biotechnology company, leader in the development of Microbiome Ecosystem TherapiesTM (MET) aimed at improving the survival of cancer patients, announces today that the Company has become a member of the Microbiome Therapeutics Innovation Group (MTIG).
To receive all of MaaT Pharma’s financial information in real time and for any questions, you can contact us via the following address: [email protected]